Elevated serum tumor necrosis factor-α levels in patients with systemic sclerosis: Association with pulmonary fibrosis

Journal of Rheumatology

Volumn 24, Issue 4, 1997, Pages 663-665

  Hasegawa, Minoru ^a   Fujimoto, Manabu ^c   Kikuchi, Kanako ^b   Takehara, Kazuhiko ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NONE

Author keywords

Pulmonary fibrosis; Systemic sclerosis; Tumor necrosis factor alpha

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDNISOLONE; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030909324     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. LeRoy EC, Smith EA, Kahaleh MB, Trojanowska M, Silver RM: A strategy for determining the pathogenesis of systemic sclerosis. Arthritis Rheum 1989;32:917-25.
2. Kovacs EJ: Fibrogenic cytokines: The role of immune mediators in the development of scar tissue. Immunology Today 1991;12:17-23.
3. Kahaleh MB: Soluble immunologic products in scleroderma sera. Clin Immunol Immunopathol 1991;58:139-44.
4. Kantor TV, Friberg D, Medsger TA Jr, Buckingham RB, Whiteside TL: Cytokine production and serum levels in systemic sclerosis. Clin Immunol Immunopathol 1992;65:278-85.
5. Needleman BW, Wigley FM, Stair RW: Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor α and interferon-γ levels in sera from patients with scleroderma. Arthritis Rheum 1992;35:67-72.
6. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
7. LeRoy EC, Krieg T, Black C, et al: Scleroderma (systemic sclerosis): Classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5.
8. Steen VD, Powell DL, Medsger TA Jr: Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988;31:196-203.
9. Thornton SC, Por SB, Walsh BJ, Penny R, Breit SN: Interaction of immune and connective tissue cells: I. The effect of lymphokines and monokines on fibroblasts growth. J Leukocyte Biol 1990;47:312-20.
10. Solis-Herruzo JA, Brenner DA, Chojkier M: Tumor necrosis factor α inhibits collagen gene transcription and collagen synthesis in cultured human fibroblasts. J Biol Chem 1988;263:5841-5.
11. Piguet PF, Grau GE, Vassalli P: Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. Am J Pathol 1990;136:103-10.
12. Zhang Y, Theodore C, Guillemin B, Yu M, Rom WN: Enhanced IL-1β and tumor necrosis factor-α release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J Immunol 1993;150:4188-96.
13. Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P: Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med 1989; 170:655-63.